文献速递神经肿瘤

甲氨蝶呤继发中枢神经系统淋巴增殖性疾病:系统文献综述与病例示例

Central Nervous System Lymphoproliferative Disorder Secondary to Methotrexate: A Systematic Literature Review and Case Illustration.
PubMed 文献 · World Neurosurg · 2023-08-12

本文通过系统文献综述(遵循PRISMA指南)结合1例病例报告,共纳入13例甲氨蝶呤相关中枢神经系统淋巴增殖性疾病(CNS MTX-LPD)病例。最常见适应证为类风湿关节炎,最常见治疗为停用甲氨蝶呤(12例,92.3%),治疗常使神经症状改善(9例,69.2%)并伴病灶消退(3例,23.1%),无复发6例(46.2%),死亡4例(30.8%),平均起病至死亡时间11个月。作者认为对服用甲氨蝶呤出现神经症状者应考虑本病,立即停药可获良好预后。

要点

  • 服用甲氨蝶呤出现神经症状者应将CNS MTX-LPD纳入鉴别诊断。
  • 最常见治疗为停用甲氨蝶呤(12例,92.3%)。
  • 治疗常使神经症状改善(9例,69.2%),死亡4例(30.8%)。

核心结论

  • 对服用甲氨蝶呤出现神经症状的患者,应考虑CNS MTX-LPD的鉴别诊断,因为立即停用甲氨蝶呤已显示良好预后。

研究设计与样本

  • 遵循PRISMA指南的系统文献综述,结合1例病例示例,共纳入13例CNS MTX-LPD病例(文献12例加本文1例)。

主要发现

  • 甲氨蝶呤最常见适应证为类风湿关节炎。
  • 淋巴增殖性疾病最常见治疗为停用甲氨蝶呤(12例,92.3%),辅助化疗2例(15.4%),全肿瘤切除3例(23.1%),类固醇治疗1例(7.7%)。
  • 治疗通常使神经症状改善(9例,69.2%)并伴病灶消退(3例,23.1%),无复发6例(46.2%)。
  • 死亡4例(30.8%),平均起病至死亡时间11个月。

临床怎么用

  • 作者认为对服用甲氨蝶呤出现神经症状的患者应考虑CNS MTX-LPD,立即停用甲氨蝶呤已显示良好预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Methotrexate is an immunosuppressant commonly used to treat inflammatory conditions, such as rheumatoid arthritis. However, albeit exceedingly rare, it can have serious adverse effects within the central nervous system (CNS), such as methotrexate-associated lymphoproliferative disorder (MTX-LPD). Literature describing the natural history, treatment options, and clinical outcomes of patients with CNS MTX-LPD remains sparse. METHODS: We present a systematic literature review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and a case illustration of CNS MTX-LPD. RESULTS: A systematic review of the literature revealed 12 published cases of CNS MTX-LPD, plus the case presented herein, for a total of 13 included cases. The most common indication for MTX was rheumatoid arthritis. The most common treatment for the LPD was MTX cessation (12, 92.3%), adjunct chemotherapy (2, 15.4%), total tumor resection (3, 23.1%), or steroid therapy (1, 7.7%). Treatment usually led to improvement of neurological symptoms (9, 69.2%) along with regression of the lesions (3, 23.1%) with no recurrence (6, 46.2%). Death was reported in four cases (30.8%) with a mean time from onset of 11 months. CONCLUSIONS: CNS MTX-LPD should be considered in the differential diagnosis for patients who are taking MTX presenting with neurologic symptoms, as immediate withdrawal of MTX has demonstrated good prognosis.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. In A, Stopa BM, Cuoco JA, et al. Central Nervous System Lymphoproliferative Disorder Secondary to Methotrexate: A Systematic Literature Review and Case Illustration. World Neurosurg. 2023. PMID: 37574195. doi:10.1016/j.wneu.2023.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。